Literature DB >> 31677788

ALKBH5-m6A-FOXM1 signaling axis promotes proliferation and invasion of lung adenocarcinoma cells under intermittent hypoxia.

Yinghui Chao1, Jin Shang2, Weidong Ji3.   

Abstract

Obstructive sleep apnea (OSA) is closely associated with cancer progression and cancer-related mortality. N6-methyladenosine (m6A) is involved in the process of intermittent hypoxia (IH) promoting tumor progression. However, it is unclear how m6A regulates the development of lung adenocarcinoma under IH. In this study, we found that ALKBH5 was elevated in lung adenocarcinoma cells and subcutaneous tumors in mice under IH, which was associated with decreased m6A levels in these cells and tissues. Next, we knocked out ALKBH5 in a human lung adenocarcinoma cell line under IH, and we found that the proliferation and invasion of these cells were significantly inhibited. Mechanistic analysis showed that under IH, knockout of ALKBH5 in lung adenocarcinoma cells upregulated the level of m6A in Forkhead box M1 (FOXM1) mRNA and decreased the translation efficiency of FOXM1 mRNA, resulting in downregulation of the FOXM1 protein. The FOXM1 protein is elevated in lung adenocarcinoma cells and subcutaneous tumor tissues of mice under IH. By knocking out FOXM1 in lung adenocarcinoma cells under IH, proliferation and invasion of these cells were inhibited, and overexpression of FOXM1 partially restored the inhibition of growth and invasion of lung adenocarcinoma cells due to ALKBH5 knockout. Collectively, our findings demonstrate that the m6A demethylase ALKBH5 affects the proliferation and invasion of lung adenocarcinoma cells under IH by downregulating m6A modification on FOXM1 mRNA and by promoting FOXM1 expression.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ALKBH5; FOXM1; Intermittent hypoxia; Lung cancer; Oncogene; m(6)A

Mesh:

Substances:

Year:  2019        PMID: 31677788     DOI: 10.1016/j.bbrc.2019.10.145

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  41 in total

1.  Bioactive peptide inhibits acute myeloid leukemia cell proliferation by downregulating ALKBH5-mediated m6A demethylation of EIF4EBP1 and MLST8 mRNA.

Authors:  Le Zhang; Xiulan Su
Journal:  Cell Oncol (Dordr)       Date:  2022-05-17       Impact factor: 7.051

Review 2.  Crosstalk among m6A RNA methylation, hypoxia and metabolic reprogramming in TME: from immunosuppressive microenvironment to clinical application.

Authors:  Fusheng Zhang; Haiyang Liu; Meiqi Duan; Guang Wang; Zhenghou Zhang; Yutian Wang; Yiping Qian; Zhi Yang; Xiaofeng Jiang
Journal:  J Hematol Oncol       Date:  2022-07-06       Impact factor: 23.168

Review 3.  m6A Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer.

Authors:  Huilin Huang; Hengyou Weng; Jianjun Chen
Journal:  Cancer Cell       Date:  2020-03-16       Impact factor: 31.743

4.  Rational Design of Novel Anticancer Small-Molecule RNA m6A Demethylase ALKBH5 Inhibitors.

Authors:  Simona Selberg; Neinar Seli; Esko Kankuri; Mati Karelson
Journal:  ACS Omega       Date:  2021-05-14

5.  ALKBH5 regulates somatic cell reprogramming in a phase-specific manner.

Authors:  Sherif Khodeer; Arne Klungland; John Arne Dahl
Journal:  J Cell Sci       Date:  2022-06-10       Impact factor: 5.235

6.  Comprehensive Analysis of N6-Methyladenosine Regulators in the Subcluster Classification and Drug Candidates Prediction of Severe Obstructive Sleep Apnea.

Authors:  Niannian Li; Zhenfei Gao; Jinhong Shen; Yuenan Liu; Kejia Wu; Jundong Yang; Shengming Wang; Xiaoman Zhang; Yaxin Zhu; Jingyu Zhu; Jian Guan; Feng Liu; Shankai Yin
Journal:  Front Genet       Date:  2022-04-26       Impact factor: 4.772

Review 7.  The emerging roles of N6-methyladenosine RNA methylation in human cancers.

Authors:  Huafei Shen; Yifen Lan; Yanchun Zhao; Yuanfei Shi; Jie Jin; Wanzhuo Xie
Journal:  Biomark Res       Date:  2020-06-29

8.  Pan-Cancer Prognostic, Immunity, Stemness, and Anticancer Drug Sensitivity Characterization of N6-Methyladenosine RNA Modification Regulators in Human Cancers.

Authors:  Rui Li; Yun-Hong Yin; Xiu-Li Ji; Xiao Liu; Jian-Ping Li; Yi-Qing Qu
Journal:  Front Mol Biosci       Date:  2021-06-04

Review 9.  The potential role of RNA N6-methyladenosine in Cancer progression.

Authors:  Tianyi Wang; Shan Kong; Mei Tao; Shaoqing Ju
Journal:  Mol Cancer       Date:  2020-05-12       Impact factor: 27.401

Review 10.  N6 -methyladenosine (m6A) RNA modification in human cancer.

Authors:  Fu-Chun Huo; Zhi-Man Zhu; Dong-Sheng Pei
Journal:  Cell Prolif       Date:  2020-10-07       Impact factor: 8.755

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.